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Comparison of the Antibacterial Effects of Two Local
Anesthetics: Lidocaine and Articaine*
Aim: The antibacterial effect of lidocaine has been studied widely, but the effect of articaine has not yet been
evaluated. We aimed to investigate whether commercially available articaine possesses bactericidal or
bacteriostatic effect in comparison with lidocaine in a prospective laboratory setting.
Materials and Methods: The antibacterial effects of articaine and lidocaine were studied on Pseudomonas
aeruginosa ATCC27853, Staphylococcus aureus ATCC25923, Escherichia coli ATCC35218, and Proteus
mirabilis ATCC7002 strains and a patient isolate of Serratia marcescens. For this study, 2% lidocaine HCl and
articaine HCl were diluted to 10, 5, 2.5, 1.25, 0.625, 0.312, 0.156, and 0.078 mg ml-1 concentrations to
determine the antibacterial effect. All bacterial strains were inoculated to 2 ml antibiotic broth at a
concentration of 5X105 m-1 for each well. For each bacterial strain, minimal bactericidal concentration (MBC)
was evaluated by inoculating the content of wells onto blood agar plates and incubating for 24 hours.
Results: MBC was detected for both of the local anesthetics. Although articaine showed bacteriostatic effect
on all bacterial strains, two of five strains were resistant to lidocaine.
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Conclusions: The finding of articaine’s bacteriostatic effect against all bacterial strains might be an evidence
for its antibacterial use.
Key Words: Local anesthetics, articaine, lidocaine, infection, bactericidal

‹ki Lokal Anestezi¤in Antibakteriyal Etkilerinin Karﬂ›laﬂt›r›lmas›:
Lidokain ve Artikain
Amaç: Lidoakainin antibakteriyal etkisi çok iyi araﬂt›r›lm›ﬂt›r, fakat artikainin etkisi henüz
de¤erlendirilmemiﬂtir. Biz artikainin ticari formunun lidokainle k›yasland›¤›nda bakterisit ya da bakteriostatik
etkisini prospektif olarak araﬂt›rmay› amaçlad›k.
Materyal ve Metot: Lidokain ve artikainin antibakteriyal etkisi Pseudomonas aeruginosa ATCC27853,
Staphylococcus aureus ATCC25923, Escherichia coli ATCC35218, Proteus mirabilis ATCC7002 suﬂlar› ve
hastadan izole edilen Serratia marcescens üzerinde araﬂt›r›ld›. Bu çal›ﬂma için %2 lidokain HCl ve artikain HCl
antibakteriyal etkiyi belirlemek için 10, 5, 2.5, 1.25, 0.625, 0.312, 0.156 ve 0.078 mg ml-1
konsantrasyonlar›na dilüe edildi. Tüm bakteri suﬂlar› her kuyucuk için 5X105 ml-1 konsantrasyon içeren 2 ml
antibiyotik broth ile inoküle edildi. Herbir bakteri için minimum bakterisit konsantrasyon (MBK) kuyucuk
içerikleri kanl› agarda 24 saat inkübe edilerek saptand›.
Bulgular: Her iki lokal anestezik için de MBK belirlendi. Artikain bu araﬂt›rmadaki tüm bakteri suﬂlar›na karﬂ›
bakteriostatik etki göstermesine ra¤men, beﬂ suﬂtan ikisi lidokaine karﬂ› dirençli bulundu.
Sonuç: Artikainin tüm bakteri suﬂlar›na karﬂ› baktriostatik olmas› bulgusu antibakteriyal kullan›m› için bir
ipucu olabilir
Anahtar Sözcükler: Lokal anestezikler; artikain, lidokain, enfeksiyon; bakterisit
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Local anesthetics occupy an important place in anesthesiology and dentistry (1-3).
Articaine, one of the most widely used local anesthetic, especially in dentistry, has been
occasionally preferred in regional anesthesia (4,5). However, it has recently been shown
that hyperbaric articaine hydrochloride was suitable for day-case spinal anesthesia (6).
Some of the drugs used in anesthesiology practice might exhibit potential for unusual
clinical uses apart from their known mechanism of action. In this respect, ketamine’s
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antibacterial effect was determined (7). The underlying
mechanism is still unknown but it could be explained by
ketamine’s local anesthetic activity in animals (8). Beyond
their anesthetic and analgesic properties, an antibacterial
effect has been demonstrated for local anesthetics like
lidocaine, bupivacaine and ropivacaine (9-13). To our
knowledge, there has been no study demonstrating the
antibacterial effect of articaine. Therefore, we aimed to
investigate the antibacterial effect of articaine on some of
the bacteria that may cause nosocomial infections, and we
compare the results with those of lidocaine.

Materials and Methods
Bacterial Strains
Five bacterial strains (Pseudomonas aeruginosa
ATCC27853, Staphylococcus aureus ATCC25923,
Escherichia coli ATCC35218, Proteus mirabilis
ATCC7002 and Serratia marcescens patient isolate) were
included in this study. The strains were grown on blood
agar plates for 24 hours (h) at 35 °C prior to the
antibacterial assay.

Antibacterial Assay
The effect of the drugs on bacterial growth was
determined by broth microdilution method. The test
medium used was antibiotic broth (Merck-Germany) for all
bacteria. In this study 10, 5, 2.5, 1.25, 0.625, 0.312,
0.156 and 0.078 mg ml-1 concentrations of local
anesthetics were tested. Aliquots (100 µl) of inoculated
double strength test media were added into micro plate
wells that already contained increasing concentrations of
drug preparations in 100 µl sterile distilled water. All
bacterial strains were inoculated to 2 ml antibiotic broth.
After a 2 h incubation at 35 °C, growth was measured by
spectrophotometer (Shimadzu-UV1201, Japan). The
densities of microorganisms were prepared according to
0.5 Mc Farland. Uninoculated test medium was used to
blank the spectrophotometer. Final bacterial
concentrations were adjusted to 5x105 ml-1 for each well.
Positive control (bacteria and growth media) and negative
control (growth media) were used for each test. For each
organism, bacteriostatic effect was defined by minimum
inhibitory concentration (MIC) and bactericidal effect was
defined as minimum bactericidal concentration (MBC).
After an incubation of 18 h at 35 °C, MIC values of local
8
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anesthetics were noted. To determine the MBC, each well
exhibiting no visible growth (viability) after 18 h was
tested for viable organisms by subculturing 10 µl samples
of each well onto blood agar. The plates were incubated at
35 °C to observe the growth of any colony after 24 h (14).

Drugs
Commercially available solutions of lidocaine
hydrochloride (Jetokain Simplex 2%, Adeka, Turkey) and
articaine hydrochloride (Ultracain 2% ampul, Aventis,
Turkey) without preservative were diluted with sterile
distilled water to produce study concentrations. The pH
values of lidocaine and articaine at 10-3 M concentration
were 7.34.
Results were expressed as visible bacterial growth
observed or not.

Results and Discussion
The antibacterial effects of the local anesthetics are
shown in Table.
Regarding all studied concentrations, articaine
inhibited growth of all bacteria included in this study (P.
aeruginosa, S. marcescens, P. mirabilis, S. aureus and E.
coli). No visible growth was observed (Table).

P. aeruginosa and S. aureus were found to be
resistant to lidocaine. E. coli had an MIC value of 5 mg
ml-1. E. coli, S. marcescens and P. mirabilis were shown
to be equally sensitive to lidocaine and articaine (Table).
MBC values were not detected with either of the local
anesthetic agents in any of the bacterial strains at the
concentrations studied.
In the present study, the bacteriostatic effects of
commercially available articaine and lidocaine have been
shown. We observed that articaine was shown to have
bacteriostatic effect against all bacteria included in this
study, whereas lidocaine was found to be bacteriostatic
against all except P. aeruginosa and S. aureus at all
concentrations studied. The bacteriostatic effects of
lidocaine and articaine were equal for E. coli, S.
marcescens and P. mirabilis, but bacteriostatic effect
appeared at 5 mg ml-1 for E. coli.
The antibacterial effect of lidocaine was well established
when combined with propofol and bicarbonate buffer
(9,15). It has also been shown that antibacterial effect was
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Table. The effect of different concentrations of lidocaine and articaine on five bacterial strains (MIC values).
Lidocaine HCl Concentration (mg ml-1)

Bacterial
Strains
0.078

P. Aeruginosa
E. Coli
P. Mirabilis
S. Aureus
S. Marcescens

+
+
+
+
+

0.156 0.312
+
+
+
+
+

+
+
+
+
+

Articaine HCl Concentration (mg ml-1)

0.625

1.25

2.5

5

10

0.078

0.156

0.312

0.625

1.25

2.5

5

10

+
+
+
+
+

+
+
+
+
+

+
+
+
+
+

+
-*
+
+
+

+
-*
+
-*

+
+
+
+
+

+
+
+
+
+

+
+
+
+
+

+
+
+
+
+

+
+
+
+
+

+
+
+
+
+

+
-*
+
+
+

-*
-*
-*
-*

+: Visible growth was observed
-: No visible growth was observed
*: MIC values

observed when lidocaine was used in bronchoalveolar
lavage fluid and tumescent liposuction (16,17). With
respect to the bacterial strains we studied, it has been
reported that lidocaine 2% had both bacteriostatic and
bactericidal effect against S. marcescens. However,
lidocaine 1% and 0.6% were found to be bactericidal and
bacteriostatic for E. coli, respectively. As for S. aureus,
lidocaine 2% and 0.2% were bactericidal and
bacteriostatic, respectively (9). Although we used lidocaine
2% corresponding to 20 mg ml-1 in our study, it became
diluted in the media and resulted in a concentration of 10
mg ml-1 corresponding to 1% at the final concentration.
Therefore, we observed only bacteriostatic effect with
lidocaine 1% against S. marcescens, which was half of the
effect demonstrated by Gajraj et al. (9). Similarly, we
observed bacteriostatic effect at 10 mg ml-1 for S.
marcescens. Our finding for E. coli was similar regarding
the bacteriostatic effect with lidocaine 0.5%, which was
observed at the half concentration.
Olsen et al. (16) demonstrated that lidocaine
decreased the viable S. pneumoniae but not P. aeruginosa
in bronchoalveolar lavage fluid, which simulates clinical
conditions better than laboratory studies. In contrast to
that study, we used bacterial growth media. The
measured pH of the growth media was between 7.2-7.4
and the two locaI anesthetics had the same pH value of
7.34. Therefore, the discrepancy in the lidocaine results
between the studies could be due to the different study
protocols.
The therapeutic plasma concentration of lidocaine has
been reported to be 1-5.6 µg ml-1 (18), and the mean
maximum plasma concentration of articaine after
submucosal injection in dentistry is 580 µg l-1 (5). With
respect to plasma concentrations, the present

bacteriostatic effects of lidocaine and articaine were much
higher than clinical plasma concentrations.
Mullin and Rubinfeld (19) demonstrated that
commercially available preserved topical local anesthetics
(proparacaine, tetracaine and cocaine) used commonly in
ophthalmology exhibited antibacterial effect in vitro on S.
aureus and P. aeruginosa, which are commonly isolated
from ophthalmic cultures. Since higher plasma
concentrations can be achieved generally at or near the
site of injection, lidocaine and articaine should be used as
a local anesthetic in case of anticipated antibacterial
effect. In contrast to plasma concentrations of the two
local anesthetics, when the commercially available
concentrations (2% for both drugs in the present study)
were taken into account, the results of this study might
provide evidence for the antibacterial effect observed in
clinical conditions.
We preferred to study these bacterial strains because
they have been the most commonly encountered
pathogens in the setting of nosocomial infections. It also
allowed for a comparison with the results reported by
Gajraj et al. (9). In the current study, we did not observe
any bactericidal effect in any of the bacterial strains.
Regarding the bacteriostatic and bactericidal effects of
lidocaine in Gajraj et al.’s (9) study, bacteriostatic and
bactericidal concentrations of lidocaine against S.
marcescens were the same (20 mg ml-1), and the
concentration difference between bacteriostatic (0.2%, 2
mg ml-1) and bactericidal (2%, 20 mg ml-1) effect was
1/10, but for E. coli this was 1/2. Though the highest
concentration we studied was 10 mg ml-1, bactericidal
effect was not observed against E. coli with either of the
local anesthetics.
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After lidocaine’s inhibitory and bactericidal activity
against a variety of organisms responsible for nosocomial
infections had been confirmed, potential application of
lidocaine in the treatment of open wounds colonized or
infected with antibiotic-resistant bacteria was
recommended by Parr et al. (20). In this respect, further
studies confirming articaine’s antibacterial activity against
different organisms might open a new window for
unusual clinical uses.
Although the underlying mechanism of the
antibacterial effect of local anesthetics is not yet clearly
understood, we assume that it might be mediated via
inhibition of cell wall synthesis or distortion of function of
cytoplasmic membrane by the local anesthetics.
Additionally, lidocaine’s membrane-stabilizing property
was known to have potent antimicrobial activity that

might compromise
microorganisms (21).
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Our study involved only aerobic bacterial strains.
Therefore, further studies might be done with anaerobic
strains for comparison. We used commercial forms of
local anesthetics without preservatives for this study
because of the necessity of investigating their possible
antibacterial effect if used in clinical practice.
Consequently, bacteriostatic effect was shown for
both lidocaine and articaine. Since this is the first study in
which articaine showed a more favorable bacteriostatic
effect than lidocaine, our results might provide
experimental support for investigating the potential
benefit of using articaine beyond its conventional
anesthetic and analgesic role in different indications,
particularly where antibacterial effect is anticipated.
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